← Back to Search

Cardiac Function Monitoring for Cardiovascular Disease

N/A
Recruiting
Research Sponsored by Sensydia Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes during cardiac catheterization procedure
Awards & highlights

Study Summary

Non-significant risk device study to conduct evaluation of the performance of new device for monitoring of cardiac function (based on previous iterations 510(k) 173156)

Eligible Conditions
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes during cardiac catheterization procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 minutes during cardiac catheterization procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cardiac Performance System electronic data for Cardiac Output
Cardiac Performance System electronic data for Pulmonary Artery Pressure
Cardiac Performance System electronic data for Pulmonary Capillary Wedge Pressure
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cardiac Function MonitoringExperimental Treatment1 Intervention
Subjects scheduled for cardiac catheterization will undergo measurement with the Cardiac Performance System non-invasive device for a brief period before the catheterization procedure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cardiac Performance System (NSR)
2020
N/A
~280

Find a Location

Who is running the clinical trial?

Sensydia CorporationLead Sponsor
3 Previous Clinical Trials
420 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~12 spots leftby Jun 2024